The ETV6 antibody is a crucial tool in studying the ETV6 protein (Ets variant 6), a transcription factor encoded by the *ETV6* gene located on human chromosome 12p13.2. ETV6 belongs to the ETS family of transcription regulators, characterized by a conserved ETS DNA-binding domain. It plays essential roles in hematopoiesis, embryonic development, and cellular differentiation by regulating gene expression through DNA binding and protein-protein interactions. Structurally, ETV6 contains an N-terminal pointed (PNT) domain, which mediates oligomerization, and a C-terminal ETS domain for DNA binding. Dysregulation of ETV6. particularly through chromosomal translocations (e.g., *ETV6-RUNX1* in pediatric B-cell acute lymphoblastic leukemia or *ETV6-NTRK3* in congenital fibrosarcoma), is implicated in various cancers, making it a significant biomarker in oncology research.
ETV6 antibodies are widely used in techniques like immunohistochemistry (IHC), Western blot (WB), and immunofluorescence (IF) to detect ETV6 expression, localization, and fusion proteins in clinical and research settings. These antibodies help identify ETV6-related oncogenic fusion products, aiding in cancer diagnosis, prognosis, and therapeutic targeting. However, challenges exist due to homology between ETV6 and other ETS family members, necessitating rigorous validation to ensure specificity. Research on ETV6 also extends to understanding its tumor-suppressive roles in certain contexts, such as modulating TGF-β signaling. Overall, ETV6 antibodies are indispensable for unraveling the dual roles of ETV6 in both normal physiology and disease pathogenesis.